EMPASHIELD L 25/5 10S

About

EMPASHIELD L 25/5 is a combination medication containing Empagliflozin 25mg and Linagliptin 5mg, indicated for the management of type 2 diabetes mellitus. Empagliflozin, an SGLT2 inhibitor, works by blocking the reabsorption of glucose in the kidneys, leading to increased glucose excretion in the urine and subsequently lowering blood glucose levels. Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that enhances the body's natural ability to lower high blood sugar by increasing the levels of incretin hormones, which stimulate insulin release and decrease glucagon secretion in a glucose-dependent manner. This dual action provides effective glycemic control, with additional benefits such as weight management and cardiovascular protection from empagliflozin, and a favorable renal safety profile for linagliptin.

Uses

• To improve glycemic control in adults with type 2 diabetes mellitus.
• Used as an adjunct to diet and exercise.
• For patients inadequately controlled on empagliflozin or linagliptin alone.
• May reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease.

Directions For Use

Take this medication orally, usually once daily in the morning, with or without food, as prescribed by your healthcare provider. Swallow the tablet whole with water.

Benefits

• Effective blood glucose control through two distinct mechanisms.
• Significant reduction in HbA1c levels.
• Potential for modest weight loss.
• May offer cardiovascular and renal protective benefits.
• Low risk of hypoglycemia when used alone.
• No dose adjustment needed for renal impairment with linagliptin.

Side Effects

• Urinary tract infections
• Genital yeast infections
• Increased urination
• Nausea
• Headache
• Nasopharyngitis
• Diarrhea
• Joint pain
• Dizziness
• Hypoglycemia (when used with insulin or sulfonylureas)
• Dehydration
• Pancreatitis (rare)

Safety Measures

• Alcohol - Limit alcohol intake as it can increase the risk of dehydration and may also increase the risk of hypoglycemia, especially with empagliflozin.
• Pregnancy - Not recommended during pregnancy, especially in the second and third trimesters, due to potential adverse effects on fetal kidney development. Consult your doctor.
• Breastfeeding - Not recommended during breastfeeding as components may pass into breast milk and could affect the infant. Consult your doctor.
• Liver - Generally no dose adjustment needed for either component, but use with caution in severe hepatic impairment.
• Kidney - Empagliflozin efficacy is reduced with declining eGFR and is not recommended below certain eGFR levels. Linagliptin does not require dose adjustment for renal impairment.
• Lung - No specific contraindication for lung conditions, but monitor for signs of respiratory infection.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.